RWE Publications - Hematology
Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
Narezkina A, Akhter N, Lu X, Emond B, Panjabi S, Forbes SP, Hilts A, Liu S, Lafeuille MH, Lefebvre P, Huang Q, Choi M. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):e959-e971.
FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA
Ailawadhi, S., Hansen, D.K., Dhakal, B. et al. FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA. Adv Ther 43, 2236–2253 (2026).
Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms
Hansen, D. K., Castaneda Puglianini, O. A., Grajales-Cruz, A. et al. Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms. Current Medical Research and Opinion, 42(2), 227–235. (2026).
IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment
Rajeeve, S., Nagar, S.P., Ghosh, S. et al. IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment. Oncol Ther 14, 1025–1041 (2026).
BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians
Banerjee, R., Hashmi, H., Chaudhary, P.M. et al. BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians. Adv Ther (2026).
FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA
Ailawadhi, S., Hansen, D.K., Dhakal, B. et al. FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA. Adv Ther 43, 2236–2253 (2026).
FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-T
Fonseca R, Sidana S, De Braganca K. et al. FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-T. Clinical Lymphoma, Myeloma and Leukemia, 26, 285-296.e4 (2026).
Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia
Mounzer E Agha, Sarah McGregor, Kevin C De Braganca, Tamar Lengil, Victoria Alegria, Denise De Wiest, Matthew Perciavalle, Ravi Potluri, Sandip Ranjan, Callum Bannister, Ahmed Mohamed, Helen Pai, Todd Bixby, Zaina P. Qureshi, Peter M Voorhees, Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia, Cancer Treatment and Research Communications, Volume 47,101161,ISSN 2468-2942 (2026).
Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases
Sidana, S., Nagar, S.P., Ghosh, S. et al. Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases. Oncol Ther 14, 827–839 (2026).
Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States
Jagannath, S., Kharat, A., Chinaeke, E., Fu, A. Z., Perciavalle, M., Huo, S., & Qureshi, Z. P. Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States. Journal of Medical Economics, 28(1), 1989–1998. (2025).
Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy
Janakiram M, Ghosh S, Alegria V, Perciavalle M, Emond B, Maitland J, Bixby T, Nagar SP, Qureshi ZP, Bakaloudi DR, Dima D. Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy. J Comp Eff Res. 2026 Jul;15(7):e260052.
Outpatient Versus Inpatient Administration of Ciltacabtagene Autoleucel in Multiple Myeloma: A Systematic Review of Clinical, Economic, and Humanistic Outcomes
Gregory T, De Braganca KC, Alegria V, Perciavalle M, Potluri R, Ranjan S, Bixby T, Qureshi ZP. Outpatient Versus Inpatient Administration of Ciltacabtagene Autoleucel in Multiple Myeloma: A Systematic Review of Clinical, Economic, and Humanistic Outcomes. Cancers. 2026; 18(5):755.
Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings
Janakiram, M., Fan, L., Ghosh, S., Alegria, V., Perciavalle, M., Emond, B., et al. Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings. Journal of Medical Economics, 29(1), 871–884. (2026).
Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma
Hansen, D. K., Lu, X., Castaneda Puglianini, O., Zhang, E., Usmani, S. Z., Sachdev, R., et al. (2026). Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Review of Pharmacoeconomics & Outcomes Research, 26(3), 369–378.
Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4
Hansen DK, Lu X, Puglianini OC, Sorensen S, Usmani SZ, Zhang E, Huo S, Zhang Y, Qureshi ZP and Jagannath S (2024) Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4. Front. Immunol. 15:1408892.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.